Patent Cliff
J&J Targets $100 Billion in 2026 Sales Despite Stelara Patent Cliff
Johnson & Johnson; J&J; 2026 sales; $100 billion; Stelara; patent cliff; DARZALEX; oncology; MedTech; Shockwave Medical
JPM26: Pfizer Fast-Tracks Obesity Programs in Race Against Patent Cliff
Pfizer; Obesity Drugs; Metsera; Phase III Trials; Albert Bourla; JPM26; Patent Cliff
Pharmas Write Big M&A Checks Again as Patent Urgency Seizes C-Suites
pharma M&A 2025; biotech acquisitions; patent cliff; pharma patent expirations; Novo Nordisk Akero deal; Johnson & Johnson Intra-Cellular acquisition; Merck Verona Pharma deal; Sanofi Blueprint Medicines acquisition; FGF21 MASH deals; 2025 healthcare deals
A closer look at pharmas top patent losses in 2025
Legal patent, Expiration, function, Market, Indication of (contextual qualifier), competition, Impact food supplement, Sales – occupational activity, Bayer, 2025, patent cliff, Regeneron, 2023
Merck & Co. predicts Keytruda will undergo IRA price cuts before patent cliff
Merck, Keytruda, Prices, IRA, Sales – occupational activity, patent cliff, Impact food supplement, U.S., Keytruda
Pfizer, Bristol Myers Squibb, and Johnson & Johnson: Navigating the Looming Patent Cliff
Patent Cliff, Pharmaceutical Industry, Pfizer, Bristol Myers Squibb, Johnson & Johnson, Patent Expirations, Biologics, Biosimilars, Revenue Loss, Mergers and Acquisitions